Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Holding BEAM?
Track your performance easily
BEAM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.84 - $49.50
Previous Close$28.93
Volume1.54M
Average Volume (3M)1.07M
Market Cap
$2.40B
Enterprise Value$1.63B
Total Cash (Recent Filing)$925.76M
Total Debt (Recent Filing)$162.06M
Price to Earnings (P/E)―
Beta2.63
Next Earnings
Mar 04, 2025EPS Estimate
-$1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding82,805,627
10 Day Avg. Volume1,107,619
30 Day Avg. Volume1,070,021
Standard Deviation0.26
R-Squared0.15
Alpha0.00555
Financial Highlights & Ratios
Price to Book (P/B)3.03
Price to Sales (P/S)6.61
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.67
Enterprise Value/Gross Profit4.32
Enterprise Value/Ebitda-11.38
Forecast
1Y Price Target
$50.17Price Target Upside75.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Beam Therapeutics News
PremiumCompany Announcements
Beam Therapeutics Advances BEAM-101 Therapy for Sickle Cell
PremiumCompany Announcements
Beam Therapeutics Names Sravan K. Emany as CFOBulls Say, Bears Say
Bulls Say
Efficacy And Market PotentialInitial data showed more than 60% increase in %HbF, indicating a potential positive outcome for the treatment.
Regulatory PathwayRegulatory precedent offers an established pathway to BEAM-101 approval.
Safety And FDA ApprovalBEAM-101 safety appears acceptable as reflected by FDA approval for inclusion of adolescents in the trial.
Bears Say
Clinical RisksThe patient death underscores the risks associated with the toxic busulfan pre-conditioning regimen, emphasizing the need for safer treatment options.
Market CompetitionBeam Therapeutics is positioned as the third company in sickle cell disease with gene editing, following competitors who are already ahead.
Valuation ConcernsBeam's high enterprise value compared to peers is not justified without clinical data.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $20.84 and its highest was $49.50 in the past 12 months.
What is Beam Therapeutics’s market cap?
Currently, no data Available
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 75 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Nov 05, 2024. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.183 by $0.013.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -$1.27.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 82,805,626 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.183. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Among the largest hedge funds holding Beam Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Beam Therapeutics’s shares valued at 201M.
---
Beam Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$50.17 (75.54% Upside)
$50.17 (75.54% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 814.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.79%
12-Months-Change
Fundamentals
Return on Equity
-18.29%
Trailing 12-Months
Asset Growth
-9.23%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
---
BEAM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of significant advancements in Beam's clinical programs, particularly in sickle cell disease and liver genetic diseases, alongside notable challenges related to patient safety in ongoing trials. While the progress in clinical data and technology development is promising, the safety concerns related to conditioning agents are a critical issue.Read More>---
BEAM Stock 12 Month Forecast
Average Price Target
$50.17
▲(75.54% Upside)
Technical Analysis
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering BEAM
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+5.69%
assigned a buy rating 10 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +5.69% per trade.
---